201 related articles for article (PubMed ID: 33177098)
1. Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy.
Xin X; Kumar V; Lin F; Kumar V; Bhattarai R; Bhatt VR; Tan C; Mahato RI
Sci Adv; 2020 Nov; 6(46):. PubMed ID: 33177098
[TBL] [Abstract][Full Text] [Related]
2. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.
Mondal G; Almawash S; Chaudhary AK; Mahato RI
Mol Pharm; 2017 Sep; 14(9):3121-3133. PubMed ID: 28719220
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
4. Cancer-associated fibroblasts promote stemness maintenance and gemcitabine resistance via HIF-1α/miR-21 axis under hypoxic conditions in pancreatic cancer.
Deng K; Zou F; Xu J; Xu D; Luo Z
Mol Carcinog; 2024 Mar; 63(3):524-537. PubMed ID: 38197482
[TBL] [Abstract][Full Text] [Related]
5. EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer.
Mondal G; Kumar V; Shukla SK; Singh PK; Mahato RI
Biomacromolecules; 2016 Jan; 17(1):301-13. PubMed ID: 26626700
[TBL] [Abstract][Full Text] [Related]
6. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
[TBL] [Abstract][Full Text] [Related]
7. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells.
He X; Wang J; Wei W; Shi M; Xin B; Zhang T; Shen X
Cancer Biol Ther; 2016; 17(2):188-98. PubMed ID: 26785721
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of miR-210 involved in epithelial-mesenchymal transition of pancreatic cancer cells under hypoxia.
Ni J; Zhou S; Yuan W; Cen F; Yan Q
J Recept Signal Transduct Res; 2019; 39(5-6):399-406. PubMed ID: 31875764
[No Abstract] [Full Text] [Related]
10. A tumor microenvironment-stimuli responsive nano-prodrug for overcoming gemcitabine chemoresistance by co-delivered miRNA-21 modulator.
Zhang F; Yao Z; Jin P; Xu M; Hu Q; Chen Y; Que R; Liang T
Biomed Mater; 2023 Apr; 18(3):. PubMed ID: 36990101
[TBL] [Abstract][Full Text] [Related]
11. Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer.
Uz M; Kalaga M; Pothuraju R; Ju J; Junker WM; Batra SK; Mallapragada S; Rachagani S
J Control Release; 2019 Jan; 294():237-246. PubMed ID: 30576747
[TBL] [Abstract][Full Text] [Related]
12. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer.
Fang Y; Zhou W; Rong Y; Kuang T; Xu X; Wu W; Wang D; Lou W
Exp Cell Res; 2019 Oct; 383(1):111543. PubMed ID: 31374207
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice.
Kattel K; Mondal G; Lin F; Kumar V; Mahato RI
Mol Pharm; 2017 May; 14(5):1365-1372. PubMed ID: 27798825
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis.
Cha ST; Chen PS; Johansson G; Chu CY; Wang MY; Jeng YM; Yu SL; Chen JS; Chang KJ; Jee SH; Tan CT; Lin MT; Kuo ML
Cancer Res; 2010 Apr; 70(7):2675-85. PubMed ID: 20233879
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer.
Kasuya K; Tsuchida A; Nagakawa Y; Suzuki M; Abe Y; Itoi T; Serizawa H; Nagao T; Shimazu M; Aoki T
Oncol Rep; 2011 Dec; 26(6):1399-406. PubMed ID: 21922147
[TBL] [Abstract][Full Text] [Related]
17. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Ma L; Fan Z; Du G; Wang H
Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.
Zhao X; Li F; Li Y; Wang H; Ren H; Chen J; Nie G; Hao J
Biomaterials; 2015 Apr; 46():13-25. PubMed ID: 25678112
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells.
Nagano H; Tomimaru Y; Eguchi H; Hama N; Wada H; Kawamoto K; Kobayashi S; Mori M; Doki Y
Int J Oncol; 2013 Oct; 43(4):1066-72. PubMed ID: 23900458
[TBL] [Abstract][Full Text] [Related]
20. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.
Shen Y; Pan Y; Xu L; Chen L; Liu L; Chen H; Chen Z; Meng Z
Tumour Biol; 2015 Jun; 36(6):4525-34. PubMed ID: 25722110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]